SCHEMBL1992243

SCHEMBL1992243

CONC(=O)C1CN(C(=O)OCc2ccccc2)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.62
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
PARP1 P09874 1/20 0.55
HTT P42858 1/20 0.51
MMP9 P14780 3/20 0.48
MMP1 P03956 2/20 0.48
MMP3 P08254 2/20 0.48
MMP7 P09237 1/20 0.48
MMP13 P45452 1/20 0.48
PDK1 Q15118 1/20 0.48
PDK2 Q15119 1/20 0.48
PDK3 Q15120 1/20 0.48
PDK4 Q16654 1/20 0.48
NPSR1 Q6W5P4 2/20 0.46
TP53 P04637 1/20 0.46
GLA P06280 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7059242 0.92 PARP1 (0.53) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL9247790 0.89 PARP1 (0.54) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL2820733 0.89 PARP1 (0.55) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL13681760 0.89 PARP1 (0.55) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL20129643 0.89 PARP1 (0.55) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL10095051 0.87 PARP1 (0.56) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL3766378 0.87 PARP1 (0.58) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL957813 0.87 PARP1 (0.58) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL1375861 0.87 PARP1 (0.58) SMN1; SMN2NPC1RAB9APARP1HTT
SCHEMBL3024872 0.87 PARP1 (0.54) SMN1; SMN2NPC1RAB9APARP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399681-B2 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2013-03-19 US disclosed
US-20120302544-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS BIGNAN GILLES (US) 2012-11-29 US disclosed
EP-2513096-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-A MODULATORS Janssen Pharmaceutica, N.V. (BE) 2012-10-24 EP disclosed
US-8263781-B2 Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 US disclosed
WO-2011075565-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 WO disclosed
US-20110150864-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302544-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS ESR2, ESRRA, IGF1R SMN1; SMN2 3292/4885NPC1 3010/4885RAB9A 3063/4885
US-20110150864-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS ESR2, ESRRA, IGF1R SMN1; SMN2 3292/4885NPC1 3010/4885RAB9A 3063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.